NWPHF (Newron Pharmaceuticals SpA) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NWPHF Newron Pharmaceuticals SpA NWPHF
64 GF Score
Price $20.00
GF Value $22.07
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA FFO per Share?

FFO per Share only applies to REITs.

NWPHF
64GF Score
Newron Pharmaceuticals SpA NWPHF
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Newron Pharmaceuticals SpA (NWPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of $20.00 is trading 9.4% below its estimated GF Value™ of $22.07.

Key valuation signals for NWPHF:

  • FFO per Share:
  • GF Value™: $22.07 vs. price of $20.00 (9.4% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the NWPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
64GF Score

Get the complete analysis for NWPHF

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.00
Price
$22.07
GF Value